These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26588681)

  • 1. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.
    Davis ZB; Felices M; Verneris MR; Miller JS
    Cancer J; 2015; 21(6):486-91. PubMed ID: 26588681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving natural killer cell cancer immunotherapy.
    Berrien-Elliott MM; Romee R; Fehniger TA
    Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
    Tonn T; Becker S; Esser R; Schwabe D; Seifried E
    J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
    Arai S; Klingemann HG
    Expert Opin Biol Ther; 2005 Feb; 5(2):163-72. PubMed ID: 15757378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
    Vahedi F; Nham T; Poznanski SM; Chew MV; Shenouda MM; Lee D; Ashkar AA
    Sci Rep; 2017 Sep; 7(1):12083. PubMed ID: 28935883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cells in cancer immunotherapy: three decades of discovery.
    Boyiadzis M; Foon KA; Herberman RB
    Discov Med; 2006 Dec; 6(36):243-8. PubMed ID: 17250791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
    Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
    Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
    Kimpo MS; Oh B; Lee S
    Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.
    Cichocki F; Verneris MR; Cooley S; Bachanova V; Brunstein CG; Blazar BR; Wagner J; Schlums H; Bryceson YT; Weisdorf DJ; Miller JS
    Curr Top Microbiol Immunol; 2016; 395():225-43. PubMed ID: 26037048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.